Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBone Marrow & SCTBTK Inhibitors: In-FocusCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR-Positive Lung CancerEndometrial CancerFollicular LymphomaHCCLung CancerMantle Cell LymphomaMPNsMultiple MyelomaRenal Cell CarcinomaSmall Cell Lung CancerThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
Spotlight
View MoreCase Based Peer PerspectivesCase-Based Roundtable SeriesClinical TrialsPodcastsPrecision MedicineSpecial Reports
NEWS
All NewsClinical FocusSpecial Reports
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
PUBLICATIONS
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Advertisement
Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Bone Marrow & SCT
  • BTK Inhibitors: In-Focus
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR-Positive Lung Cancer
  • Endometrial Cancer
  • Follicular Lymphoma
  • HCC
  • Lung Cancer
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
SpotlightSee All >
  • Case Based Peer Perspectives
  • Case-Based Roundtable Series
  • Clinical Trials
  • Podcasts
  • Precision Medicine
  • Special Reports
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Radioligand Therapy 177Lu-PSMA-617 in Patients With Progressive PSMA-positive mCRPC

Evan Y. Yu, MD, reviews the use of LuPSMA radioligand therapy and the role of precision medicine in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

EP. 1: Role of Precision Medicine in PSMA-Positive mCRPC

August 20th 2021

Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.

EP. 2: PSMA-Positive mCRPC: Phase 3 VISION Trial

August 20th 2021

Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.

EP. 3: Patient Response to LuPSMA Therapy in mCRPC

August 20th 2021

An expert in prostate cancer comments on patient response to 177Lu-PSMA-617 therapy, particularly for patients with mCRPC who have liver metastases.

EP. 4: Phase 2 TheraP Trial in PSMA-Positive mCRPC

August 20th 2021

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

EP. 5: Sequencing of LuPSMA Therapy in PSMA-Positive mCRPC

August 20th 2021

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.

Advertisement
Advertisement